$XBI $137.3 +2.2%
Covid Updates
$SRNE +10.6% Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July. source
Pipeline Updates
$RCUS +15.5% On 6/23 Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study. source
$RVMD -0.5% Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1. source
$TERN +1.9% Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201. source
$EOLS -0.8% Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color. source
$PRTA +1.6% Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration. source
$KURA +3.2% Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539. source
$SLS -3.8% SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo. source
$AGLE +8.0% Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria. source
$CRBP +4.0% Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis. source
$PTCT +1.7% Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone. source
$AQST -2.7% Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film. source
$ALPN +4.6% Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration. source
$LGVN +4.9% Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference. source
$PIRS +23.5% Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer. source
$VECT +1.7% VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease. source
$VKTX +4.4% Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD. source
$AGTC +3.6% AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene. source
$ARAV +5.3% Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma. source
$FULC -4.0% Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function. source
$EGRX +4.9% Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin. source
Financial Updates
$ETNB +13.2% Presented at Raymond James Human Health Innovation Conference 6/23 on "Current Thinking in Nash". source
$ANVS +1.3% Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards. source
Posted by FS
Commentaires